Yoga therapy on elderly patients with fear of fall: an open-label randomised controlled trial (YOFEAR trial)

被引:0
|
作者
Kashyap, Kritartha [1 ]
Dhar, Minakshi [1 ,2 ]
Bisht, Khushboo [3 ]
Bahurupi, Yogesh [4 ]
Pathania, Monika [1 ]
机构
[1] All India Inst Med Sci, Geriatr Med, Rishikesh, Uttarakhand, India
[2] All India Inst Med Sci, Internal Med, Rishikesh, Uttarakhand, India
[3] All India Inst Med Sci, Clin Pharmacol, Rishikesh, Uttarakhand, India
[4] All India Inst Med Sci, Community & Family Med, Rishikesh, Uttarakhand, India
来源
BMJ OPEN | 2023年 / 13卷 / 12期
关键词
GERIATRIC MEDICINE; Health & safety; Quality in health care; Aging; REHABILITATION MEDICINE; OLDER-PEOPLE; BALANCE; GAIT; COMMUNITY; EFFICACY; ADULTS; VALIDATION; EXERCISES;
D O I
10.1136/bmjopen-2022-070540
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Fear of fall is experienced by the elderly irrespective of the presence or absence of history of fall. Falls contribute to injuries that culminate in hospitalisation that incur unwarranted medical expenses. Yoga is unique to Indian cultural practices, with a potential to enhance proprioception. It increases self-body awareness, ultimately improving the balancing capacity of older adults. Thus, the objective of this study is to compare the effect of yoga therapy in the study and control groups at 12 weeks from the baseline.Methods and analysis This study is designed as an open-label, randomised controlled trial (1:1) with a sample size of 62 elderly patients more than or equal to 60 years of age. Participation of either sex, male or female with a fear of fall will be considered. Two randomised groups of 31 participants each will receive standard therapy for their primary diseases as per the local, national or international guidelines. However, participants in the intervention arm will receive additional structured yoga therapy sessions. The primary objective of this study is to assess and compare the change in fear of fall score of participants in each group using Falls Efficacy Scale (FES) and Berg Balance Scale (BBS) at 12 weeks versus baseline. The secondary endpoint will assess the change in the quality of life of participants at 3 months compared with the baseline. Data will be gathered, entered into Microsoft Excel and further analysed by R software (V.4.3.0). Changes in FES-Intervention and BBS of two groups will be compared either by Student's t-test for parametric data or Mann-Whitney U test for non-parametric data. Statistical significance will be considered if p<0.05 at 95% confidence level.Methods and analysis This study is designed as an open-label, randomised controlled trial (1:1) with a sample size of 62 elderly patients more than or equal to 60 years of age. Participation of either sex, male or female with a fear of fall will be considered. Two randomised groups of 31 participants each will receive standard therapy for their primary diseases as per the local, national or international guidelines. However, participants in the intervention arm will receive additional structured yoga therapy sessions. The primary objective of this study is to assess and compare the change in fear of fall score of participants in each group using Falls Efficacy Scale (FES) and Berg Balance Scale (BBS) at 12 weeks versus baseline. The secondary endpoint will assess the change in the quality of life of participants at 3 months compared with the baseline.Data will be gathered, entered into Microsoft Excel and further analysed by R software (V.4.3.0). Changes in FES-Intervention and BBS of two groups will be compared either by Student's t-test for parametric data or Mann-Whitney U test for non-parametric data. Statistical significance will be considered if p<0.05 at 95% confidence level.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Effect of ranolazine as add-on therapy in type 2 diabetic dyslipidaemia patients: A randomised open-label trial
    Ravula, Sahithya Ravali
    Karunanidhi Santhana, Lakshmi
    Thangavel Mahalingam, Vijayakumar
    Janardanan Subramonia, Kumar
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (04)
  • [42] Cyclophosphamide following mitoxantrone therapy: an open-label trial
    Decoo, D
    Meire, V
    MULTIPLE SCLEROSIS, 2005, 11 : S171 - S171
  • [43] Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial
    Kaura, Amit
    Sztriha, Laszlo
    Chan, Fong Kum
    Aeron-Thomas, John
    Gall, Nicholas
    Piechowski-Jozwiak, Bartlomiej L.
    Teo, James T.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2019, 24 (1)
  • [44] Open-label placebo treatment of women with premenstrual syndrome: study protocol of a randomised controlled trial
    Nascimento, Antje Frey
    Gaab, Jens
    Kirsch, Irving
    Kossowsky, Joe
    Meyer, Andrea
    Locher, Cosima
    BMJ OPEN, 2020, 10 (02):
  • [45] Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial
    Amit Kaura
    Laszlo Sztriha
    Fong Kum Chan
    John Aeron-Thomas
    Nicholas Gall
    Bartlomiej Piechowski-Jozwiak
    James T. Teo
    European Journal of Medical Research, 24
  • [46] Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial
    Tripura, Rupam
    von Seidlein, Lorenz
    Sovannaroth, Siv
    Peto, Thomas J.
    Callery, James J.
    Sokha, Meas
    Ean, Mom
    Heng, Chhouen
    Conradis-Jansen, Franca
    Madmanee, Wanassanan
    Peerawaranun, Pimnara
    Waithira, Naomi
    Khonputsa, Panarasri
    Jongdeepaisal, Monnaphat
    Pongsoipetch, Kulchada
    Chotthanawathit, Paphapisa
    Soviet, Ung
    Pell, Christopher
    Duanguppama, Jureeporn
    Rekol, Huy
    Tarning, Joel
    Imwong, Mallika
    Mukaka, Mavuto
    White, Nicholas J.
    Dondorp, Arjen M.
    Maude, Richard J.
    LANCET INFECTIOUS DISEASES, 2023, 23 (01): : 81 - 90
  • [47] Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial
    Sekhavati, Ehsan
    Jafari, Fatemeh
    SeyedAlinaghi, SeyedAhmad
    Jamalimoghadamsiahkali, Saeidreza
    Sadr, Sara
    Tabarestani, Mohammad
    Pirhayati, Mohammad
    Zendehdel, Abolfazl
    Manafi, Navid
    Hajiabdolbaghi, Mahboubeh
    Ahmadinejad, Zahra
    Kouchak, Hamid Emadi
    Jafari, Sirous
    Khalili, Hosein
    Salehi, Mohamadreza
    Seifi, Arash
    Golestan, Fereshteh Shahmari
    Ghiasvand, Fereshteh
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (04)
  • [48] Open-label placebo for insomnia (OPIN): study protocol for a cohort multiple randomised controlled trial
    Colagiuri, Ben
    Sharpe, Louise
    Ambarchi, Zahava
    Glozier, Nick
    Bartlett, Delwyn
    Costa, Daniel S. J.
    Scott, Amelia
    BMJ OPEN, 2021, 11 (02):
  • [49] Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial
    Teper, Alejandro
    Jaques, Anna
    Charlton, Brett
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (01) : 1 - 8
  • [50] Open-Label Placebo Administration Decreases Pain in Elderly Patients With Symptomatic Knee Osteoarthritis - A Randomized Controlled Trial
    Olliges, Elisabeth
    Stroppe, Sabine
    Haile, Anja
    Reiss, Fabienne
    Malhis, Marwa
    Funke, Susanne A.
    Meissner, Karin
    FRONTIERS IN PSYCHIATRY, 2022, 13